262 related articles for article (PubMed ID: 33537174)
1. Characterization of CD8
Shinkawa T; Tokita S; Nakatsugawa M; Kikuchi Y; Kanaseki T; Torigoe T
Oncoimmunology; 2021 Jan; 10(1):1870062. PubMed ID: 33537174
[TBL] [Abstract][Full Text] [Related]
2. Proteogenomic identification of an immunogenic HLA class I neoantigen in mismatch repair-deficient colorectal cancer tissue.
Hirama T; Tokita S; Nakatsugawa M; Murata K; Nannya Y; Matsuo K; Inoko H; Hirohashi Y; Hashimoto S; Ogawa S; Takemasa I; Sato N; Hata F; Kanaseki T; Torigoe T
JCI Insight; 2021 Jul; 6(14):. PubMed ID: 34185709
[TBL] [Abstract][Full Text] [Related]
3. Proteogenomic discovery of cancer antigens: Neoantigens and beyond.
Kanaseki T; Tokita S; Torigoe T
Pathol Int; 2019 Sep; 69(9):511-518. PubMed ID: 31397525
[TBL] [Abstract][Full Text] [Related]
4. Apparent Lack of
Kemps PG; Zondag TC; Steenwijk EC; Andriessen Q; Borst J; Vloemans S; Roelen DL; Voortman LM; Verdijk RM; van Noesel CJM; Cleven AHG; Hawkins C; Lang V; de Ru AH; Janssen GMC; Haasnoot GW; Franken KLMC; van Eijk R; Solleveld-Westerink N; van Wezel T; Egeler RM; Beishuizen A; van Laar JAM; Abla O; van den Bos C; van Veelen PA; van Halteren AGS
Front Immunol; 2019; 10():3045. PubMed ID: 31998317
[TBL] [Abstract][Full Text] [Related]
5. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
[TBL] [Abstract][Full Text] [Related]
6. Mutation position is an important determinant for predicting cancer neoantigens.
Capietto AH; Jhunjhunwala S; Pollock SB; Lupardus P; Wong J; Hänsch L; Cevallos J; Chestnut Y; Fernandez A; Lounsbury N; Nozawa T; Singh M; Fan Z; de la Cruz CC; Phung QT; Taraborrelli L; Haley B; Lill JR; Mellman I; Bourgon R; Delamarre L
J Exp Med; 2020 Apr; 217(4):. PubMed ID: 31940002
[TBL] [Abstract][Full Text] [Related]
7. HLA-A24 ligandome analysis of colon and lung cancer cells identifies a novel cancer-testis antigen and a neoantigen that elicits specific and strong CTL responses.
Kochin V; Kanaseki T; Tokita S; Miyamoto S; Shionoya Y; Kikuchi Y; Morooka D; Hirohashi Y; Tsukahara T; Watanabe K; Toji S; Kokai Y; Sato N; Torigoe T
Oncoimmunology; 2017; 6(4):e1293214. PubMed ID: 28533942
[TBL] [Abstract][Full Text] [Related]
8. Breast Cancer Neoantigens Can Induce CD8
Zhang X; Kim S; Hundal J; Herndon JM; Li S; Petti AA; Soysal SD; Li L; McLellan MD; Hoog J; Primeau T; Myers N; Vickery TL; Sturmoski M; Hagemann IS; Miller CA; Ellis MJ; Mardis ER; Hansen T; Fleming TP; Goedegebuure SP; Gillanders WE
Cancer Immunol Res; 2017 Jul; 5(7):516-523. PubMed ID: 28619968
[TBL] [Abstract][Full Text] [Related]
9. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
10. Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen.
Chen P; Chen D; Bu D; Gao J; Qin W; Deng K; Ren L; She S; Xu W; Yang Y; Xie X; Liao W; Chen H
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37076248
[TBL] [Abstract][Full Text] [Related]
11. Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.
Newey A; Griffiths B; Michaux J; Pak HS; Stevenson BJ; Woolston A; Semiannikova M; Spain G; Barber LJ; Matthews N; Rao S; Watkins D; Chau I; Coukos G; Racle J; Gfeller D; Starling N; Cunningham D; Bassani-Sternberg M; Gerlinger M
J Immunother Cancer; 2019 Nov; 7(1):309. PubMed ID: 31735170
[TBL] [Abstract][Full Text] [Related]
12. Discovery of U2AF1 neoantigens in myeloid neoplasms.
Biernacki MA; Lok J; Black RG; Foster KA; Cummings C; Woodward KB; Monahan T; Oehler VG; Stirewalt DL; Wu D; Rongvaux A; Deeg HJ; Bleakley M
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38164756
[TBL] [Abstract][Full Text] [Related]
13. An immunogenic personal neoantigen vaccine for patients with melanoma.
Ott PA; Hu Z; Keskin DB; Shukla SA; Sun J; Bozym DJ; Zhang W; Luoma A; Giobbie-Hurder A; Peter L; Chen C; Olive O; Carter TA; Li S; Lieb DJ; Eisenhaure T; Gjini E; Stevens J; Lane WJ; Javeri I; Nellaiappan K; Salazar AM; Daley H; Seaman M; Buchbinder EI; Yoon CH; Harden M; Lennon N; Gabriel S; Rodig SJ; Barouch DH; Aster JC; Getz G; Wucherpfennig K; Neuberg D; Ritz J; Lander ES; Fritsch EF; Hacohen N; Wu CJ
Nature; 2017 Jul; 547(7662):217-221. PubMed ID: 28678778
[TBL] [Abstract][Full Text] [Related]
14. Identification of patient-specific CD4
Cattaneo CM; Battaglia T; Urbanus J; Moravec Z; Voogd R; de Groot R; Hartemink KJ; Haanen JBAG; Voest EE; Schumacher TN; Scheper W
Nat Biotechnol; 2023 Jun; 41(6):783-787. PubMed ID: 36593398
[TBL] [Abstract][Full Text] [Related]
15. Neoantigens as potential vaccines in hepatocellular carcinoma.
Repáraz D; Ruiz M; Llopiz D; Silva L; Vercher E; Aparicio B; Egea J; Tamayo-Uria I; Hervás-Stubbs S; García-Balduz J; Castro C; Iñarrairaegui M; Tagliamonte M; Mauriello A; Cavalluzzo B; Buonaguro L; Rohrer C; Heim K; Tauber C; Hofmann M; Thimme R; Sangro B; Sarobe P
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193931
[TBL] [Abstract][Full Text] [Related]
16. Elevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genes.
Castro A; Ozturk K; Pyke RM; Xian S; Zanetti M; Carter H
BMC Med Genomics; 2019 Jul; 12(Suppl 6):107. PubMed ID: 31345234
[TBL] [Abstract][Full Text] [Related]
17. Identification of shared neoantigens in esophageal carcinoma by the combination of comprehensive analysis of genomic data and in silico neoantigen prediction.
Yuan Y; Chen C; Liu S; Xiong H; Huang Y; Zhang X; Zhang X; Li B
Cell Immunol; 2022 Jul; 377():104537. PubMed ID: 35636066
[TBL] [Abstract][Full Text] [Related]
18. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis.
Turajlic S; Litchfield K; Xu H; Rosenthal R; McGranahan N; Reading JL; Wong YNS; Rowan A; Kanu N; Al Bakir M; Chambers T; Salgado R; Savas P; Loi S; Birkbak NJ; Sansregret L; Gore M; Larkin J; Quezada SA; Swanton C
Lancet Oncol; 2017 Aug; 18(8):1009-1021. PubMed ID: 28694034
[TBL] [Abstract][Full Text] [Related]
19. Effect of secondary anchor amino acid substitutions on the immunogenic properties of an HLA-A*0201-restricted T cell epitope derived from the Trypanosoma cruzi KMP-11 protein.
Lasso P; Cárdenas C; Guzmán F; Rosas F; Thomas MC; López MC; González JM; Cuéllar A; Campanera JM; Luque FJ; Puerta CJ
Peptides; 2016 Apr; 78():68-76. PubMed ID: 26854383
[TBL] [Abstract][Full Text] [Related]
20. T Cell Recognition of Tumor Neoantigens and Insights Into T Cell Immunotherapy.
Sim MJW; Sun PD
Front Immunol; 2022; 13():833017. PubMed ID: 35222422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
